Redefining Obesity Treatment Through Metabolic Science
We develop first-in-class therapies that activate the body’s own energy-burning pathways, delivering innovative, personalized solutions to improve health and quality of life.
About us
Eolo Pharma is a clinical-stage biotechnology company pioneering new approaches to treat obesity and metabolic disease. By targeting the body’s energy expenditure pathways, we aim to develop transformative therapies that go beyond traditional weight-loss mechanisms. Our lead candidate, SANA, is the first compound shown to safely activate creatine-dependent thermogenesis in humans, a novel biological process with the potential to reset metabolic health. Backed by over a decade of research, our work reflects a commitment to advancing science-driven solutions that improve lives worldwide.
Our
Pipeline
Our NCE library is composed of 60 novel molecules. Within our pipeline we highlight MVD1, our lead compound for Obesity and its comorbidities.
|
Indications
|
Program
|
Drug Candidate
|
Discovery & chracterization
|
Phase I
|
Phase II
|
Phase III
|
|---|---|---|---|---|---|---|
|
Obesity T2 Diabetes NASH Hypertension
|
Oral thermogenic NCE
|
|||||
|
MVD 1 analog
|
||||||
|
NCE
|
||||||
|
ALS Alzheimer's
|
NF-kB inhibitor & other
|
Eolo40
|
||||
|
MVD-1
|
||||||
Science
At Eolo Pharma, we apply state-of-the-art biomedical research and mechanism-based drug design to develop first-in-class therapies targeting energy balance and metabolic dysfunction. Our work is rooted in unlocking underexplored biological pathways to deliver scientifically validated treatments that improve patient outcomes worldwide.
Our library of novel chemical entities (NCEs) includes a proprietary collection of small molecules designed to address high-burden, non-communicable diseases. Among them, we highlight MVD1, a lead candidate in our pipeline targeting obesity and its associated metabolic disorders.
Dive into
our world
Research at Eolo
Discover our collection of peer-reviewed publications, unveiling groundbreaking research in various fields. Engage with our insightful works that bridge science and innovation, offering valuable insights into obesity, ALS, and tissue transplantation. Join us in exploring the forefront of knowledge and unlocking new possibilities in healthcare.
Nature Metabolism: A nitroalkene derivative of salicylate, SANA, induces creatine-dependent thermogenesis and promotes weight loss
A Nitroalkene Benzoic Acid Derivative Targets Reactive Microglia and Prolongs Survival in an Inherited Model of ALS via NF-κB Inhibition.
A novel nitroalkene vitamin E analogue inhibits the NLRP3 inflammasome and protects against inflammation and glucose intolerance triggered by obesity
Electrophilic nitroalkene-tocopherol derivatives: synthesis, physicochemical characterization and evaluation of anti-inflammatory signaling responses
Eolo Pharma is a company dedicated to improving the health and well-being of individuals. Our high-quality products are designed to enhance energy and vitality, providing innovative solutions for healthcare.
Copyright © 2024 EoloPharma. All rights reserved.